[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postoperative-atrial-fibrillation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postoperative-atrial-fibrillation":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,40,67,92,119,144,166,200,221,247],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100650964","the-effect-of-ligament-of-marshall-excision-during-minimally-invasive-cardiac-surgery-coronary-artery-bypass-grafting-mics-cabg-on-the-prevention-of-postoperative-new-onset-atrial-fibrillation-a-multicenter-prospective-randomized-triple-blinded-study-100650964",false,"NCT07755072","The Effect of Ligament of Marshall Excision During Minimally Invasive Cardiac Surgery-Coronary Artery Bypass Grafting (MICS-CABG) on the Prevention of Postoperative New-Onset Atrial Fibrillation: A Multicenter, Prospective, Randomized, Triple-Blinded Study","Inclusion Criteria:\n\n* Aged 18-80 years;\n* Coronary artery lesions meeting the indications for surgical revascularization, with planned MICS-CABG;\n* Signed an informed consent form agreeing to participate in the study;\n\nExclusion Criteria:\n\n* Patients with preoperative hemodynamic instability requiring emergency surgery;\n* History of paroxysmal or persistent atrial fibrillation prior to surgery;\n* Echocardiographic left atrial anteroposterior diameter (APD) ≥ 60 mm;\n* Patients with ejection fraction (EF) \\\u003C 40%, left ventricular diastolic dimension (LVDD) \\> 60 mm, left ventricular aneurysm, or severe arrhythmia who are at high risk of intraoperative hemodynamic instability;\n* Patients with concomitant mitral stenosis or regurgitation of moderate severity or greater;\n* Patients undergoing concurrent valve surgery or other intracardiac corrective procedures;\n* Patients with a history of renal insufficiency;\n* Patients receiving intra-aortic balloon pump (IABP) or extracorporeal membrane oxygenation (ECMO) circulatory support preoperatively;\n* Patients taking antiarrhythmic drugs other than beta-blockers prior to surgery, such as propafenone or amiodarone;\n* History of cardiac or thoracic surgery;\n* Poor pulmonary function, with a preoperative arterial blood gas analysis oxygen partial pressure (PaO₂) \\\u003C 60 mmHg at rest without oxygen supplementation;\n* Patients with a preoperative pacemaker implant;","ALL","18 Years","80 Years",{"count":19,"type":20},628,"ESTIMATED","INTERVENTIONAL",[23],"NA","After heart bypass surgery, many patients develop a heart rhythm problem called postoperative atrial fibrillation, or POAF for short. This issue happens to 20%-40% of all bypass patients. Even with smaller, less invasive surgical cuts or robot-assisted heart bypass operations, between 4.8% and 18.4% of people still get POAF.\n\nWhen POAF occurs, patients usually stay in the hospital longer and face higher medical bills. It also raises chances of serious complications like stroke, heart failure and heart attacks, and lowers long-term survival rates. Stopping POAF early is therefore key to helping patients recover better after surgery.\n\nPOAF comes from two main causes: personal health risks and stress from the surgery itself. Older age, high blood pressure, heart failure, lung disease, diabetes and overweight all make people more likely to develop irregular heart rhythms after an operation. Surgical trauma also plays a big role: cutting the breastbone, fluid building up around the heart, inflammation from heart-lung machines, pulling or stitching heart tissue, and unbalanced nerve signals during recovery can all spark POAF. Earlier studies have shown simple surgical adjustments can lower POAF risk safely, giving us a good basis to improve current surgery methods.\n\nThe Ligament of Marshall is a fibrous bundle-like structure left over from heart development before birth. Its special tissue structure makes it easy to trigger chaotic heart beats. It holds muscle tissue that creates looping abnormal electrical signals, plus nerve clusters that overactivate the body's stress response after surgery - this is a major cause of POAF. Doctors who fix irregular heart rhythms with catheter burns already target this ligament to stop repeat atrial fibrillation. Major heart surgery for long-term irregular heartbeats also routinely cuts this ligament without adding extra surgical risks.\n\nOur study will collect real clinical data to deepen the understanding of POAF and partial denervation therapy. Cutting the Ligament of Marshall during minimally invasive cardiac surgery-coronary artery bypass grafting (MICS-CABG) is an easy, low-risk step with no extra risk of collateral injury. We hope this method can lower the chance of irregular heartbeats after surgery, reduce the need for rhythm-control drugs and their side effects, and help patients maintain stable heart function and better daily life right after surgery.\n\nFor MICS-CABG, doctors do not need extra complicated steps to see and cut the Ligament of Marshall. We only make a small cut between the ribs on the left chest. After pericardial incision and suspension, this fibrous bundle-like structure is clearly visible and simple to operate on. Compared with traditional open-heart surgery that splits the whole breastbone, this small-cut approach avoids rough handling of the left heart and lessens overall surgical stress on patients.",[26],"Postoperative Atrial Fibrillation","NOT_YET_RECRUITING","2026-08-04",{"date":30,"type":31},"2026-08-10","ACTUAL",{"date":33,"type":20},"2026-07-13",{"date":35,"type":20},"2028-01-31",{"name":37,"class":38},"Peking University Third Hospital","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100649034","phase-4-perioperative-statins-to-prevent-afib-after-lung-surgery-100649034","NCT07727681","Perioperative Statins to Prevent AFib After Lung Surgery","Perioperative Statin Therapy for the Prevention of Atrial Fibrillation After Anatomical Lung Resection: A Randomized Controlled Trial","STAT-LUNG","Inclusion Criteria:\n\n* Age 60 years or older.\n* Scheduled to undergo isolated anatomical lung resection, including pulmonary segmentectomy or lobectomy.\n* Sinus rhythm documented by a preoperative electrocardiogram.\n* Not receiving antiarrhythmic medication, with the exception of beta-blockers.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Untreated hyperthyroidism or hypothyroidism.\n* History of obstructive hepatobiliary disease, active liver disease, or other serious liver disease.\n* Preoperative serum creatinine greater than 150 μmol\u002FL.\n* Known allergy to atorvastatin or another statin, or a history of a serious statin-related adverse reaction, including statin-associated myopathy.\n* Personal or family history of an inherited muscle disorder.\n* Continuous use within 1 month before randomization of fibrates, niacin, or medications that strongly inhibit cytochrome P450 or P-glycoprotein, including cyclosporine, oral azole antifungal agents, certain interacting antibiotics, protease inhibitors, nefazodone, or amiodarone.\n* Consumption of 1 liter or more of grapefruit juice per day within 1 month before randomization.\n* Current treatment with a high-intensity statin regimen, including atorvastatin 40 mg\u002Fday or higher or rosuvastatin 20 mg\u002Fday or higher.\n* Any other condition that, in the investigator's judgment, would make participation unsafe or interfere with the conduct or evaluation of the study.","60 Years",{"count":50,"type":20},540,[52],"PHASE4","The goal of this clinical trial is to learn whether short-term treatment with atorvastatin can prevent new abnormal rapid heart rhythms after lung surgery in adults aged 60 years or older who are scheduled to have a lung segment or lung lobe removed. The study will also evaluate the safety of short-term atorvastatin treatment around the time of surgery.\n\nThe main questions this study aims to answer are:\n\n* Does perioperative atorvastatin lower the number of participants who develop atrial fibrillation or a related rapid rhythm from the upper chambers of the heart during the first 72 hours after surgery?\n* What medical problems or changes in liver, kidney, or muscle-related laboratory tests occur during treatment?\n\nParticipants will be assigned by chance to receive either short-term atorvastatin treatment or a matching placebo-based comparison treatment. A placebo is a look-alike tablet that does not contain atorvastatin. Participants who were already taking a statin (moderate-intensity) before the study will receive a standardized background statin regimen so that their usual treatment is not stopped unnecessarily. Neither the participants nor most members of the research team will know which treatment has been assigned.\n\nStudy treatment will usually begin 2 to 7 days before surgery and continue until 72 hours after surgery. After surgery, participants will wear a portable heart monitor continuously for 72 hours to identify abnormal heart rhythms. Researchers will also collect routine clinical information, blood test results, and safety information during the hospital stay and will follow participants for 30 days after surgery.",[26,55],"Lung Surgery","RECRUITING","2026-07-25",{"date":59,"type":31},"2026-07-28",{"date":61,"type":20},"2026-08-01",{"date":63,"type":20},"2028-01-02",{"name":65,"class":38},"Peking Union Medical College Hospital",2,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":39},"100606318","quality-of-life-in-patients-with-postoperative-atrial-fibrillation-after-cardiac-surgery-100606318","NCT07173998","Quality of Life in Patients With Postoperative Atrial Fibrillation After Cardiac Surgery","Prospective Observational Study on Quality of Life With Postoperative Atrial Fibrillation","Inclusion Criteria:\n\n* All genders\n* Ages 18-99 years old\n* Scheduled to undergo cardiac surgery\n* Able to answer survey questions\n\nExclusion Criteria:\n\n* Persistent \u002F permanent atrial fibrillation\n* Atrial fibrillation at presentation for surgery\n* Emergent operations","100 Years",{"count":76,"type":20},260,"OBSERVATIONAL","Prospective observational study on quality of life with postoperative atrial fibrillation after cardiac surgery using SF-36 and qualitative questions",[26],[81,82],"cardiac surgery","recovery","2026-06-26",{"date":85,"type":31},"2026-06-29",{"date":87,"type":31},"2025-07-15",{"date":89,"type":20},"2027-07-01",{"name":91,"class":38},"Brigham and Women's Hospital",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":39},"100520268","predictive-value-of-right-atrial-strain-in-postoperative-atrial-fibrillation-in-patients-undergoing-cardiac-surgery-100520268","NCT06054360","Predictive Value of Right Atrial Strain in Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery","ODFAPO","Inclusion Criteria:\n\n* Adult patient (\\>18 years old)\n* The patient was hospitalized at the Amiens University Hospital for scheduled aortocoronary bypass grafting under cardiopulmonary bypass.\n* Echocardiographic image quality enabling the measurement of RAS parameters\n* Patient affiliation to a social security scheme\n* Patient\u002Fproxy information and collection of their non-opposition.\n\nExclusion Criteria:\n\n* Patients participating in an interventional study may modify the incidence of POAF.\n* History of atrial fibrillation or flutter.\n* Valvular and ascending aorta cardiac surgery\n* Urgent cardiac surgery.\n* Presence of tricuspid insufficiency greater than grade 2.\n* Left ventricular ejection fraction lower than 50%.\n* Patient receiving circulatory mechanical assistance before surgery.\n* Dependency on ventricular and atrial pacing by an internal or external cardiac pacemaker during the echocardiographic examination.",{"count":100,"type":20},334,"The incidence of postoperative atrial fibrillation (POAF) after cardiac surgery is around 30%. POAF increases the risk of developing permanent atrial fibrillation and raises the risk of cardiac decompensation, stroke, acute myocardial infarction, and death. While the role of the left atrium (LAF) in the pathophysiology of POAF is now well-established, the part of the right atrium (RA) remains poorly understood. Recent studies suggest a correlation between RA function and POAF.\n\nRA function can be assessed by transthoracic echocardiography (TTE) with dedicated software for measuring the RA strain (RAS). RA function is thus divided into three phases: reservoir (RASr), conduit, and contraction. Numerous studies have demonstrated that a significant alteration in RAS predicts POAF in various clinical contexts. Therefore, it is essential to investigate whether alterations in RA function assessed by 2D-STE (RAS) are associated with an increased occurrence of FAPO after cardiac surgery.\n\nIt is essential to investigate whether alterations in RA function assessed by 2D-STE (RAS) are associated with an increased occurrence of FAPO after cardiac surgery.",[26,103],"Strains",[105,106,107,108,109],"coronary bypass grafting","postoperative atrial fibrillation","strain","left atrial","right atrial","2026-05-27",{"date":112,"type":31},"2026-05-28",{"date":114,"type":31},"2023-10-09",{"date":116,"type":20},"2026-10-09",{"name":118,"class":38},"Centre Hospitalier Universitaire, Amiens",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":21,"phases":128,"briefSummary":129,"conditions":130,"keywords":131,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":39},"100412997","multiparametric-mri-assessment-of-atrial-heart-disease-as-a-predictor-of-atrial-fibrillation-after-myocardial-revascularization-surgery-100412997","NCT04657835","Multiparametric MRI Assessment of Atrial Heart Disease as a Predictor of Atrial Fibrillation After Myocardial Revascularization Surgery","IRM-FAPO","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Indication for surgical myocardial revascularization by isolated coronary artery bypass grafting, to be performed in the cardiac surgery department of Saint-Étienne University Hospital.\n* Patient affiliated with or entitled to social security coverage\n* Patient who has received informed information about the study and has co-signed, with the investigator, a consent form to participate in the study\n\nExclusion Criteria:\n\n* Contraindication related to cardiac MRI\n* Contraindication related to ILR implantation\n* Documented history of atrial fibrillation\n* Concomitant indication for valve surgery or other associated cardiac intervention\n* Inability to understand French\n* Patient refusal to participate in the study and\u002For inability to express consent or sign the informed consent form\n* Patient subject to legal protection measures",{"count":127,"type":20},100,[23],"Postoperative atrial fibrillation (POAF) occurs in 20-40% of patients undergoing coronary artery bypass grafting (CABG) and is a marker of atrial vulnerability. It is strongly associated with AF recurrence, stroke, and cardiovascular mortality. It presents risk factors with atrial heart disease.\n\nThe latter refers to all structural, electrical, and mechanical alterations of the atrium that create a substrate conducive to AF.\n\nMultiparametric cardiac MRI is currently the most comprehensive test for assessing atrial heart disease, thanks to its structural and functional analysis (atrial fibrosis, atrial strain, intracavitary 4D flow). However, to date, no prospective study has evaluated these parameters as predictors of AF recurrence after CAP. At the same time, an implantable Holter monitor will be used to enable detailed and continuous detection of recurrence episodes, overcoming the limitations of conventional monitoring strategies. By combining multiparametric imaging, histological analysis, and continuous monitoring for the first time, this study proposes a paradigm shift in the assessment of postoperative AF: moving from a descriptive and ad hoc approach to a mechanistic, integrative, and predictive approach.",[26],[132,133,134],"magnetic resonance imaging","implantable holter monitor","atrial heart disease","2026-03-03",{"date":137,"type":31},"2026-03-05",{"date":139,"type":20},"2026-05-01",{"date":141,"type":20},"2028-12",{"name":143,"class":38},"Centre Hospitalier Universitaire de Saint Etienne",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":151,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":21,"phases":154,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":39},"100352383","phase-4-prevention-of-postop-atrial-fibrillation-through-intraoperative-inducibility-of-atrial-fibrillation-and-amiodarone-treatment-100352383","NCT03868150","Prevention of Postop Atrial Fibrillation Through Intraoperative Inducibility of Atrial Fibrillation and Amiodarone Treatment","Assessment of Intra-Operative Atrial Fibrillation Inducibility As a Screening Tool to Prevent Post-Operative Atrial Fibrillation With Prophylaxis Amiodarone","Inclusion Criteria:\n\n* Patients scheduled for first-time non-emergent open-heart surgery for coronary artery bypass graft (CABG) revascularization, valvular repair or replacement, combined CABG with valve repair or replacement, or valve sparing aortic root repair\n* Normal sinus rhythm\n* No documented history of atrial fibrillation\n\nExclusion Criteria:\n\n* Prior surgical procedures involving heart surgery and cardiopulmonary bypass\n* Any prior documented history of atrial fibrillation, atrial flutter or atrial tachycardia lasting longer than 30 seconds\n* Prior history of Amiodarone treatment for the management of supraventricular tachy-arrhythmias\n* Patients requiring surgical treatment of atrial arrhythmias such as pulmonary vein isolation or Maze procedure.",true,{"count":153,"type":20},600,[52],"Patients undergoing first time cardiac surgery will undergo rapid atrial pacing prior to initiation of cardiopulmonary bypass to screen for AF inducibility. Patients with inducible AF will be randomized to prophylactic amiodarone treatment versus no treatment. Patients who are not inducible to AF will be treated with standard post-operative care. Patients will be monitored post-operatively to explore the value of intraoperative inducibility of AF to predict POAF and to evaluate whether the combination of intraoperative inducibility and precision amiodarone therapy is effective at reducing the incidence of POAF",[26],"2026-02-12",{"date":159,"type":31},"2026-02-17",{"date":161,"type":31},"2017-03-01",{"date":163,"type":20},"2050-12-31",{"name":165,"class":38},"Stanford University",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":176,"conditions":177,"keywords":184,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":39},"100571781","diagnosis-of-atrial-fibrillation-in-postoperative-thoracic-surgery-using-a-smartwatch-100571781","NCT06724718","Diagnosis of Atrial Fibrillation in Postoperative Thoracic Surgery Using a Smartwatch","THO-FA-WATCH","Inclusion Criteria:\n\n* Adults (\\>18 years old).\n* Patients undergoing major thoracic surgery with one-lung ventilation within the past 48 hours.\n* Scheduled pneumonectomy or lobectomy.\n* Admission to a conventional surgical unit postoperatively.\n* Ability to perform single-lead ECG using a smartwatch.\n* Coverage under a social security system.\n* Signed informed consent\n\nExclusion Criteria:\n\n* History of atrial fibrillation.\n* Requirement for telemetry for AV block or tachyarrhythmias (\\>140 bpm).\n* Dependency on a pacemaker.\n* Participation in another interventional clinical trial affecting POAF incidence.\n* Mediastinal, pleural, or chest wall surgery.\n* Reoperations or surgeries performed more than 48 hours prior.\n* Pregnant women.\n* Patients under guardians or similar legal protection.",{"count":174,"type":20},302,[23],"Postoperative atrial fibrillation (POAF) occurs in approximately 20% of patients following thoracic surgery. Early diagnosis is essential to prevent complications such as heart failure, stroke, myocardial infarction, and increased mortality. Smartwatches equipped with single-lead ECG capabilities and algorithms to detect asymptomatic atrial fibrillation (AF) offer a potential solution. This study aims to evaluate the effectiveness of smartwatches in detecting POAF compared to standard care.",[26,178,179,180,181,182,183],"Thoracic Surgery","Smartwatches","Rhythm Monitoring","Cardiovascular Prognosis","Asymptomatic Atrial Fibrillation","Randomized Trial",[185,186,187,188,189,190,191],"Postoperative atrial fibrillation","thoracic surgery","smartwatches","rhythm monitoring","cardiovascular prognosis","asymptomatic atrial fibrillation","randomized trial","2025-06-11",{"date":194,"type":31},"2025-06-12",{"date":196,"type":31},"2025-06-01",{"date":198,"type":20},"2027-12",{"name":118,"class":38},{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":21,"phases":209,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":39},"100444039","post-operative-atrial-fibrillation-after-surgical-aortic-valve-replacement-and-the-influence-of-statins-100444039","NCT05062239","Post-Operative Atrial Fibrillation After Surgical Aortic Valve Replacement and the Influence of Statins","Post-Operative Atrial Fibrillation After Surgical Aortic Valve Replacement and the Influence of Statins - Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients undergoing elective solitary SAVR with bioprosthesis\n2. Patients who are in sinus rhythm and not taking any anti-arrhythmic medication, other than beta-adrenergic blocking agents, at the time of surgery\n3. In treatment with HMG-CoA reductase inhibitors in the past 3 months and of at least 7 days\n4. Age \\>60 years\n5. Willingness and provision of informed consent to be randomized\n\nExclusion Criteria:\n\n1. Prior history of atrial fibrillation\n2. Prior history of cardiac surgery\n3. Hepatic dysfunction (Alanin-aminotransferase more than twice the upper limit)\n4. Creatinine \\>200 µmol\u002FL","95 Years",{"count":127,"type":20},[23],"Statins have rapid and significant actions that have potentially important (but not yet proven) implications for postoperative atrial fibrillation and cardiac protection in patients undergoing cardiac surgery.\n\nThe focus of this study is, therefore, on patients having surgical aortic valve replacement (with aortotomy) and the development of postoperative atrial fibrillation (POAF).\n\nOur aims are: to investigate the risk of POAF, infection or other complications after SAVR in continuous versus preoperative discontinuous treatment with statins.\n\nThe study is a single centre randomized controlled trial with continuance treatment with statin vs. discontinuance (7 to 14 days prior surgery until the 30th post-operative day included), on patients undergoing elective solitary SAVR with bioprosthesis with prior usage of statins the last 3 months and of at least 7 days.\n\nThis randomized studies will address 2 separate hypotheses in patients undergoing open heart operation with solitary aortic valve replacement with a bioprosthetic valve that\n\n1. Discontinuation of HMG-CoA reductase inhibitors 7 to 14 days preoperative until 30 days postoperative of AVR in patients with prior use of HMG-CoA reductase inhibitors is not associated with increased early (\\\u003C30 days) risk of POAF.\n2. Discontinuation of HMG-CoA reductase inhibitors 7 to 14 days preoperative until 30 days postoperative of AVR in patients with prior use of HMG-CoA reductase inhibitors is not associated with increased early (\\\u003C30 days) and intermediate (\\\u003C1 year) risk of mortality, MI, stroke and rehospitalisation.",[26],"2025-04-22",{"date":214,"type":31},"2025-04-23",{"date":216,"type":31},"2022-04-01",{"date":218,"type":20},"2027-02-01",{"name":220,"class":38},"Lars Peter Riber",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":21,"phases":231,"briefSummary":232,"conditions":233,"keywords":234,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":39},"100579398","prophylactic-radiofrequency-left-atrial-posterior-wall-isolation-to-prevent-atrial-fibrillation-after-cardiac-surgery-100579398","NCT06823778","Prophylactic Radiofrequency Left Atrial Posterior Wall Isolation to Prevent Atrial Fibrillation After Cardiac Surgery","Prophylactic Radiofrequency Left Atrial Posterior Wall Isolation (box Lesion Ablation) to Prevent Atrial Fibrillation After Cardiac Surgery (PROBOX): a Randomized Controlled Trial","PROBOX","Inclusion Criteria:\n\n* All patients undergoing cardiac surgery by a single surgeon (V.K.)\n* Informed consent\n\nExclusion Criteria:\n\n* History of atrial fibrillation\u002Fflutter\n* Minimally invasive approach\n* Off-pump surgery\n* Emergent\u002Fsalvage surgery\n* Severe pericardial adhesions",{"count":230,"type":20},216,[23],"The goal of this clinical trial is to learn if an epicardial radiofrequency left atrial posterior wall isolation (box lesion ablation) prevents atrial fibrillation after cardiac surgery. The main question it aims to answer is:\n\n\\- Does box lesion ablation lower the number of patients experiencing de-novo atrial fibrillation requiring any treatment after cardiac surgery? Researchers will compare box lesion ablation to no ablation to see if ablation prevents postoperative atrial fibrillation.\n\nParticipants will undergo ablation or no ablation at the time of other cardiac surgery.\n\nData will be collected while in hospital. Additional information will be collected on 30th day after surgery by telephone call or during a visit.",[26],[26,235,236,237],"Radiofrequency Ablation","Box Lesion Ablation","Prophylactic Ablation","2025-02-19",{"date":240,"type":31},"2025-02-21",{"date":242,"type":31},"2025-02-17",{"date":244,"type":20},"2027-09",{"name":246,"class":38},"Vasily I. Kaleda",{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":207,"enrollmentInfo":255,"targetDuration":4,"studyType":21,"phases":257,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":39},"100445098","statin-therapy-with-atorvastatin-in-surgical-aortic-valve-replacement-100445098","NCT05076019","Statin Therapy With Atorvastatin in Surgical Aortic Valve Replacement","Statin Therapy With Atorvastatin in Surgical Aortic Valve Replacement - a Randomized Controlled Trial","STARC","Inclusion Criteria:\n\n1. Patients undergoing elective solitary SAVR with bioprosthesis\n2. Patients who are in sinus rhythm and not taking any anti-arrhythmic medication, other than beta-adrenergic blocking agents, at the time of surgery\n3. No prior use of HMG-CoA reductase inhibitors the last 3 months and at least 7 days prior to the time of surgery\n4. Age \\>60 years\n5. Willingness and provision of informed consent to be randomized\n\nExclusion Criteria:\n\n1. Prior history of atrial fibrillation\n2. Prior history of cardiac surgery\n3. Known adverse reaction to HMG-CoA reductase inhibitors\n4. Hepatic dysfunction (Alanin-aminotransferase more than twice the upper limit)\n5. Creatinine \\>200 µmol\u002FL\n6. Known intolerance to statins or history of muscle toxicity with statins\n7. Known intolerance to any of the excipients in Lipistad\n8. Treatment with anti-viral medicine (glecaprevir\u002Fpibrentasvir) for hepatitis",{"count":256,"type":20},266,[23],"Statins have rapid and significant actions that have potentially important (but not yet proven) implications for postoperative atrial fibrillation and cardiac protection in patients undergoing cardiac surgery.\n\nThe focus of this study is, therefore, on patients having surgical aortic valve replacement (with aortotomy) and the development of postoperative atrial fibrillation (POAF). Our aims are: to examine the ability of a clinically durable Atorvastatin prophylactic regime to prevent the development of POAF and other postoperative complications in these patients.\n\nPatients will be randomized to Atorvastatin 80mg or placebo 7 to 14 days preoperative until 30 days postoperative - a total of 37 to 44 days of treatment.\n\nThe medication will be double blinded.\n\nThe randomized studie will address the following hypotheses in patients undergoing open heart operation with solitary aortic valve replacement with a bioprosthetic valve that\n\n1\\) 7 to 14 days preoperative and until 30 days postoperative treatment with Atorvastatin 80 mg daily reduces the incidence of POAF in statin-naïve patients.",[26],"2024-10-07",{"date":262,"type":31},"2024-10-08",{"date":264,"type":31},"2022-02-01",{"date":266,"type":20},"2027-12-01",{"name":268,"class":38},"Odense University Hospital"]